Pharmacy, Cwm Taf Morgannwg University Health Board, Abercynon, Rhondda Cynon Taff CF45 4SN, United Kingdom.
Pharmacy Department, Maudsley Hospital, LondonSE5 8AZ, United Kingdom.
Eur Psychiatry. 2021 Feb 3;64(1):e11. doi: 10.1192/j.eurpsy.2021.4.
Outcomes with long-acting injections (LAIs) are generally better than with oral antipsychotic therapy. However, the use of LAIs does not assure compliance with treatment and in clinical practice patients often miss injections or receive their injections later than intended.
We conducted a case-control study to identify demographic and treatment associations with relapse (cases) on paliperidone 1-monthly injection (PP1M) compared with age-, gender-, and ethnicity-matched controls.
We identified 16 cases and matched 43 controls. Baseline variables did not differ except that cases had received significantly more antipsychotic drugs before initiation with PP1M (3.94 vs. 2.12; p < 0.001). Cases had fewer PP1M injections administered compared with the control group (9.69 vs. 11.37; p < 0.001) and this group had a longer interval between injections than the control group (37 vs. 33 days; p < 0.001).
Relapse on PP1M is associated with reduced frequency of injection and a longer interval between doses.
长效注射剂（LAIs）的治疗效果通常优于口服抗精神病药物治疗。然而，使用 LAI 并不能保证患者始终遵医嘱治疗，在临床实践中，患者经常错过注射或未能按时接受注射。
我们进行了一项病例对照研究，以确定与棕榈酸帕利哌酮 1 个月注射（PP1M）相关的复发（病例）的人口统计学和治疗相关因素，与年龄、性别和种族相匹配的对照组进行比较。
我们确定了 16 例病例，并匹配了 43 例对照。除了病例在开始使用 PP1M 之前接受的抗精神病药物数量明显更多（3.94 与 2.12；p<0.001）外，基线变量没有差异。与对照组相比，病例组接受的 PP1M 注射次数较少（9.69 与 11.37；p<0.001），并且该组的注射间隔时间长于对照组（37 与 33 天；p<0.001）。
PP1M 治疗的复发与注射频率降低和剂量间隔延长有关。
